PMID- 37916160
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231103
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 13
DP  - 2023
TI  - Efficacy and safety of transarterial chemoembolization combined with lenvatinib 
      and camrelizumab in patients with BCLC-defined stage C hepatocellular carcinoma.
PG  - 1244341
LID - 10.3389/fonc.2023.1244341 [doi]
LID - 1244341
AB  - OBJECTIVE: To investigate the effectiveness and safety of combining transarterial 
      chemoembolization (TACE) with lenvatinib and camrelizumab in patients with 
      Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC). 
      METHODS: We retrospectively analyzed 141 patients with BCLC stage C HCC: 57 were 
      treated with TACE combined with lenvatinib plus camrelizumab (T + L + C), 41 were 
      treated with TACE combined with camrelizumab (T + C), and 43 were treated with 
      TACE (TACE). The primary outcomes were overall survival (OS) and progression-free 
      survival (PFS), and the secondary outcomes were the objective response rate (ORR) 
      and adverse events (AEs). Factors that affected survival were identified via Cox 
      regression analysis. RESULTS: Comparison of the three groups revealed a 
      significant difference in the median overall survival (mOS), 19.8 months (95% CI 
      15.7-23.9) in the T + L + C combined group vs 15.7 (95% CI 13.1-18.3) months in 
      the T + C combined group vs 9.4 (95% CI 6.2-12.5) months in the TACE group (P < 
      0.001). The median progression-free survival (mPFS) was significantly better in 
      the T + L + C combination group than in the T + C combination group and the TACE 
      group [11.4 (95% CI 7.6-15.3) months vs 8.4 (95% CI 6.2-10.5) months vs 4.8 (95% 
      CI 3.2-6.3) months, respectively, P < 0.001)]. The objective response rate (ORR) 
      (57.9%) and the disease control rate (DCR) (75.4%) patients in the combined T + L 
      + C group were higher than those in the other two groups. More patients in the 
      combined T + L + C group experienced AEs, with 16 (28.1%) patients experiencing 
      AEs of grade 3 or higher. CONCLUSIONS: In patients with BCLC stage C HCC, those 
      receiving the T + L + C combination demonstrated a superior survival benefit and 
      acceptable safety profile compared patients receiving either TACE or the T + C 
      combination.
CI  - Copyright (c) 2023 Wu, Zeng, Wang, Huo, Hou and He.
FAU - Wu, Juan
AU  - Wu J
AD  - Department of Interventional Radiology, Harbin Medical University Cancer 
      Hospital, Harbin, Heilongjiang, China.
FAU - Zeng, Jia
AU  - Zeng J
AD  - Department of Interventional Radiology, Harbin Medical University Cancer 
      Hospital, Harbin, Heilongjiang, China.
FAU - Wang, Huiwen
AU  - Wang H
AD  - Department of Interventional Radiology, Harbin Medical University Cancer 
      Hospital, Harbin, Heilongjiang, China.
FAU - Huo, Zhuoni
AU  - Huo Z
AD  - Department of Interventional Radiology, Harbin Medical University Cancer 
      Hospital, Harbin, Heilongjiang, China.
FAU - Hou, Xunbo
AU  - Hou X
AD  - Department of Interventional Radiology, Harbin Medical University Cancer 
      Hospital, Harbin, Heilongjiang, China.
FAU - He, Dongfeng
AU  - He D
AD  - Department of Interventional Radiology, Harbin Medical University Cancer 
      Hospital, Harbin, Heilongjiang, China.
LA  - eng
PT  - Journal Article
DEP - 20231017
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC10616839
OTO - NOTNLM
OT  - camrelizumab
OT  - efficacy
OT  - hepatocellular carcinoma
OT  - lenvatinib
OT  - transarterial chemoembolization
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/11/02 06:42
MHDA- 2023/11/02 06:43
PMCR- 2023/01/01
CRDT- 2023/11/02 04:14
PHST- 2023/06/22 00:00 [received]
PHST- 2023/09/25 00:00 [accepted]
PHST- 2023/11/02 06:43 [medline]
PHST- 2023/11/02 06:42 [pubmed]
PHST- 2023/11/02 04:14 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2023.1244341 [doi]
PST - epublish
SO  - Front Oncol. 2023 Oct 17;13:1244341. doi: 10.3389/fonc.2023.1244341. eCollection 
      2023.